Table 2.
Clinical results of lagre randomized trials
| Trial | Agent | Drug name | Disease type | Primary outcome | Result on primary outcome |
|---|---|---|---|---|---|
| Jacobs et al, 19988,16 | Interferon beta-1a | Avonex | Relapsing-remitting | Time to confirmed progression | Positive |
| Interferon beta-1a | Avonex | Secondary progressive | Time to confirmed progression | Trial still ongoing | |
| Interferon beta-1a | Avonex | After 1st attack | Time to 2nd attack | Positive | |
| Interferon beta-1a | Avonex | Primary progressive | Time to confirmed progression | Presented as negative; not yet published | |
| PRISMS Study Group, 19989 | Interferon beta-1a | Rebif | Relapsing-remitting | Relapse rate | Positive |
| SPECTRIMS study* | Interferon beta-1a | Rebif | Secondary progressive | Time to confirmed progression | Presented as negative |
| Comi et al, 199515 | Interferon beta-1a | Rebif | After 1st attack | Time to 2nd attack | Presented as positive; not yet published |
| INFB Multiple Sclerosis Study Group, 1993 | Interferon beta-1b | Betaseron | Relapsing-remitting | Relapse rate | Positive |
| European Study Group, 199820 | Interferon beta-1b | Betaseron | Secondary progressive | Time to confirmed progression | Positive |
| Interferon beta-1b | Betaseron | Secondary progressive | Time to confirmed progression | Presented as negative; not yet published | |
| Johnson et al, 199511 | Glatiramer acetate | Copaxone | Relapsing-remitting | Relapse rate | Positive |
*
Abstract only; not yet published.